Eli Lilly and Company (NYSE:LLY) Shares Up 3.9% – Should You Buy?

Eli Lilly and Company (NYSE:LLY) traded up 3.9% during mid-day trading on Wednesday . The company traded as high as $976.68 and last traded at $955.4470. 6,165,708 shares changed hands during trading, an increase of 91% from the average session volume of 3,220,580 shares. The stock had previously closed at $919.77.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP?1 weight?loss pill Foundayo — a major commercial catalyst that expands the company’s obesity franchise into an oral, scalable offering and intensifies competition with Novo Nordisk. This approval is the primary near?term bullish trigger. Lilly’s weight-loss pill wins US approval
• Positive Sentiment: Market commentary and options pricing point to further upside after Foundayo’s approval — analysts and options markets are pricing an expectation of higher LLY moves over the next 1–3 months. Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (deal up to ~$7.8B), adding sleep?wake disorder assets and diversifying beyond obesity/diabetes — a strategic M&A move that supports longer?term revenue growth and reduces single?product concentration risk. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Unusual call?option activity: unusually large volume of LLY calls was traded today, consistent with bullish positioning from traders expecting further share gains.
• Positive Sentiment: Lilly’s big AI and R&D investments (multi?billion partnerships) signal a pipeline acceleration strategy that supports a premium valuation over the medium term. Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?
• Neutral Sentiment: Novo Nordisk’s pricing/subscription moves for Wegovy keep competitive pressure on pricing and market share for obesity drugs — increases industry competition but doesn’t negate Foundayo’s market entry. Novo Nordisk (NVO) Stock: New Wegovy Subscription Pricing Takes on Eli Lilly
• Neutral Sentiment: An investor law?firm inquiry into the Centessa sale process was filed — watch for procedural noise, but this is a common occurrence in M&A and not yet a material operational threat. Centessa Pharmaceuticals Investor Alert
• Negative Sentiment: Lilly’s CEO publicly opposed codifying the “Most Favored Nations” (MFN) drug pricing deals into law — this stance could attract policy scrutiny and political risk around pricing reforms. Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says
• Negative Sentiment: Guggenheim lowered near?term expectations for LLY — an analyst downgrade or reduced estimates can weigh on sentiment even amid positive company news. Guggenheim Has Lowered Expectations for Eli Lilly

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. Bank of America dropped their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.26.

Eli Lilly and Company Stock Up 3.9%

The firm’s 50-day moving average is $1,001.75 and its two-hundred day moving average is $966.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a market cap of $902.72 billion, a P/E ratio of 41.63, a PEG ratio of 1.03 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same period last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.